Cargando…
A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival
SIMPLE SUMMARY: Through implementation of HPV testing as standard primary screening method, the number of women diagnosed with high-grade cervical intraepithelial neoplasia (CIN2-3) has increased. Although only one third of CIN3 will progress to cancer, conization is standard treatment in high-incom...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616457/ https://www.ncbi.nlm.nih.gov/pubmed/34830895 http://dx.doi.org/10.3390/cancers13225737 |
_version_ | 1784604353225555968 |
---|---|
author | Halle, Mari K. Munk, Ane Cecilie Engesæter, Birgit Akbari, Saleha Frafjord, Astri Hoivik, Erling A. Forsse, David Fasmer, Kristine E. Woie, Kathrine Haldorsen, Ingfrid S. Bertelsen, Bjørn I. Janssen, Emiel A. M. Gudslaugsson, Einar Krakstad, Camilla Øvestad, Irene T. |
author_facet | Halle, Mari K. Munk, Ane Cecilie Engesæter, Birgit Akbari, Saleha Frafjord, Astri Hoivik, Erling A. Forsse, David Fasmer, Kristine E. Woie, Kathrine Haldorsen, Ingfrid S. Bertelsen, Bjørn I. Janssen, Emiel A. M. Gudslaugsson, Einar Krakstad, Camilla Øvestad, Irene T. |
author_sort | Halle, Mari K. |
collection | PubMed |
description | SIMPLE SUMMARY: Through implementation of HPV testing as standard primary screening method, the number of women diagnosed with high-grade cervical intraepithelial neoplasia (CIN2-3) has increased. Although only one third of CIN3 will progress to cancer, conization is standard treatment in high-income countries. The aim of this study was to identify tools with which to predict CIN regression relevant for individualizing treatment within this patient group. We compared the transcriptomic immune-profile from 21 lesions with confirmed regression and 28 lesions with confirmed persistent CIN3. A gene signature with high sensitivity to identify CIN3 lesions that regressed during follow-up was identified. When tested in a cervical cancer cohort (n = 239) with available transcriptomic data, a high regression signature score was associated with favorable survival, small tumors, and immune infiltration. This study presents a gene signature with the capacity to predict CIN regression, that may potentially guide treatment, and identifies common disease drivers in CIN and cervical cancer. ABSTRACT: The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with confirmed regression and 28 with persistent CIN3 were compared. L1000 mRNA data from a cervical cancer cohort was available for validation (n = 239). Transcriptomic analyses identified TDO2 (p = 0.004), CCL5 (p < 0.001), CCL3 (p = 0.04), CD38 (p = 0.02), and PRF1 (p = 0.005) as upregulated, and LCK downregulated (p = 0.01) in CIN3 regression as compared to persistent CIN3 lesions. From these, a gene signature predicting CIN3 regression with a sensitivity of 91% (AUC = 0.85) was established. Transcriptomic analyses revealed proliferation as significantly linked to persistent CIN3. Within the cancer cohort, high regression signature score associated with immune activation by Gene Set enrichment Analyses (GSEA) and immune cell infiltration by histopathological evaluation (p < 0.001). Low signature score was associated with poor survival (p = 0.007) and large tumors (p = 0.01). In conclusion, the proposed six-gene signature predicts CIN regression and favorable cervical cancer prognosis and points to common drivers in precursors and cervical cancer lesions. |
format | Online Article Text |
id | pubmed-8616457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86164572021-11-26 A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival Halle, Mari K. Munk, Ane Cecilie Engesæter, Birgit Akbari, Saleha Frafjord, Astri Hoivik, Erling A. Forsse, David Fasmer, Kristine E. Woie, Kathrine Haldorsen, Ingfrid S. Bertelsen, Bjørn I. Janssen, Emiel A. M. Gudslaugsson, Einar Krakstad, Camilla Øvestad, Irene T. Cancers (Basel) Article SIMPLE SUMMARY: Through implementation of HPV testing as standard primary screening method, the number of women diagnosed with high-grade cervical intraepithelial neoplasia (CIN2-3) has increased. Although only one third of CIN3 will progress to cancer, conization is standard treatment in high-income countries. The aim of this study was to identify tools with which to predict CIN regression relevant for individualizing treatment within this patient group. We compared the transcriptomic immune-profile from 21 lesions with confirmed regression and 28 lesions with confirmed persistent CIN3. A gene signature with high sensitivity to identify CIN3 lesions that regressed during follow-up was identified. When tested in a cervical cancer cohort (n = 239) with available transcriptomic data, a high regression signature score was associated with favorable survival, small tumors, and immune infiltration. This study presents a gene signature with the capacity to predict CIN regression, that may potentially guide treatment, and identifies common disease drivers in CIN and cervical cancer. ABSTRACT: The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with confirmed regression and 28 with persistent CIN3 were compared. L1000 mRNA data from a cervical cancer cohort was available for validation (n = 239). Transcriptomic analyses identified TDO2 (p = 0.004), CCL5 (p < 0.001), CCL3 (p = 0.04), CD38 (p = 0.02), and PRF1 (p = 0.005) as upregulated, and LCK downregulated (p = 0.01) in CIN3 regression as compared to persistent CIN3 lesions. From these, a gene signature predicting CIN3 regression with a sensitivity of 91% (AUC = 0.85) was established. Transcriptomic analyses revealed proliferation as significantly linked to persistent CIN3. Within the cancer cohort, high regression signature score associated with immune activation by Gene Set enrichment Analyses (GSEA) and immune cell infiltration by histopathological evaluation (p < 0.001). Low signature score was associated with poor survival (p = 0.007) and large tumors (p = 0.01). In conclusion, the proposed six-gene signature predicts CIN regression and favorable cervical cancer prognosis and points to common drivers in precursors and cervical cancer lesions. MDPI 2021-11-16 /pmc/articles/PMC8616457/ /pubmed/34830895 http://dx.doi.org/10.3390/cancers13225737 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Halle, Mari K. Munk, Ane Cecilie Engesæter, Birgit Akbari, Saleha Frafjord, Astri Hoivik, Erling A. Forsse, David Fasmer, Kristine E. Woie, Kathrine Haldorsen, Ingfrid S. Bertelsen, Bjørn I. Janssen, Emiel A. M. Gudslaugsson, Einar Krakstad, Camilla Øvestad, Irene T. A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title_full | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title_fullStr | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title_full_unstemmed | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title_short | A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival |
title_sort | gene signature identifying cin3 regression and cervical cancer survival |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616457/ https://www.ncbi.nlm.nih.gov/pubmed/34830895 http://dx.doi.org/10.3390/cancers13225737 |
work_keys_str_mv | AT hallemarik agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT munkanececilie agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT engesæterbirgit agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT akbarisaleha agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT frafjordastri agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT hoivikerlinga agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT forssedavid agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT fasmerkristinee agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT woiekathrine agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT haldorseningfrids agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT bertelsenbjørni agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT janssenemielam agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT gudslaugssoneinar agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT krakstadcamilla agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT øvestadirenet agenesignatureidentifyingcin3regressionandcervicalcancersurvival AT hallemarik genesignatureidentifyingcin3regressionandcervicalcancersurvival AT munkanececilie genesignatureidentifyingcin3regressionandcervicalcancersurvival AT engesæterbirgit genesignatureidentifyingcin3regressionandcervicalcancersurvival AT akbarisaleha genesignatureidentifyingcin3regressionandcervicalcancersurvival AT frafjordastri genesignatureidentifyingcin3regressionandcervicalcancersurvival AT hoivikerlinga genesignatureidentifyingcin3regressionandcervicalcancersurvival AT forssedavid genesignatureidentifyingcin3regressionandcervicalcancersurvival AT fasmerkristinee genesignatureidentifyingcin3regressionandcervicalcancersurvival AT woiekathrine genesignatureidentifyingcin3regressionandcervicalcancersurvival AT haldorseningfrids genesignatureidentifyingcin3regressionandcervicalcancersurvival AT bertelsenbjørni genesignatureidentifyingcin3regressionandcervicalcancersurvival AT janssenemielam genesignatureidentifyingcin3regressionandcervicalcancersurvival AT gudslaugssoneinar genesignatureidentifyingcin3regressionandcervicalcancersurvival AT krakstadcamilla genesignatureidentifyingcin3regressionandcervicalcancersurvival AT øvestadirenet genesignatureidentifyingcin3regressionandcervicalcancersurvival |